Key Highlights:
- Pfizer's stock has experienced a dramatic decline, offering a potentially favorable entry point for investors.
- The stock boasts a high dividend yield of 7.5%, coupled with an attractive valuation based on its price-to-earnings ratio.
- Future prospects appear promising with ongoing acquisitions and drug development initiatives.
Pfizer Inc. (PFE, Financial) has experienced a notable drop in its stock price since reaching its peak in 2022, now sitting over 63% lower. Despite this decline, the company offers a substantial dividend yield of 7.5% alongside an appealing low price-to-earnings ratio, presenting a potential growth opportunity. Investors may be intrigued by Pfizer's strategic acquisitions and innovative drug developments which could offer rewarding prospects amid the current market uncertainty.
Wall Street Analysts' Predictions for Pfizer
According to projections from 19 analysts, the one-year average price target for Pfizer Inc. (PFE, Financial) stands at $30.86. This target includes a high estimate of $41.43 and a low of $25.00. The average target implies a potential upside of 41.32% from the current stock price of $21.84. Investors seeking more in-depth analysis can explore further on the Pfizer Inc (PFE) Forecast page.
The consensus recommendation among 23 brokerage firms for Pfizer Inc. is 2.5, indicating an "Outperform" status. The rating system spans from 1 to 5, with 1 representing a Strong Buy and 5 indicating a Sell.
GuruFocus estimates suggest the GF Value for Pfizer Inc. (PFE, Financial) one year from now to be $28.68, indicating an upside of 31.32% from the current price of $21.84. The GF Value represents GuruFocus' calculated fair value at which the stock should trade, derived from historical multiples, past business growth, and future performance projections. For more comprehensive information, visit the Pfizer Inc (PFE) Summary page.
